
Podcast #93 · 19 Nov 2026
From Neoadjuvant and Perioperative Therapy to Surgery: Multidisciplinary Decisions in Early Stage NSCLC
- Smoking Cessation
- Multidisciplinary Care
- Medical Oncology
- Interventional Pulmonology
- Non-Small Cell Lung Cancer (NSCLC)
- Thoracic Surgery
- Thoracic Oncology
- Next-Generation Sequencing (NGS)
- Adjuvant Therapy
- Neoadjuvant Therapy
- Lobectomy
- Tumor Board
- Liquid Biopsy
- Lymph Node Dissection
- Circulating Tumor DNA (ctDNA)
- PD-L1
“If I have a complete pathological response, why do I need to get surgery?” It is one of the hottest questions in early-stage non-small cell lung cancer (NSCLC), and Dr. John Lazar hears it from his patients after neoadjuvant therapy. On this episode of the BackTable Lung Cancer Creator Weekend™, medical oncologist Dr. Kate Baker talks with Dr. Lazar, thoracic surgeon at Ascension Saint Thomas, about who should get neoadjuvant or perioperative therapy and how tumor size, nodal disease, histology, and molecular profiling shape the plan. They also discuss what a complete pathologic response does and does not tell a patient, why waiting more than six weeks from diagnosis to treatment raises the risk of upstaging, and how surgery changes after treatment has distorted the anatomy.
This podcast is supported by
Timestamps
Resources
More about this episode
Dr. Kate Baker and Dr. John Lazar trade questions across the surgeon and medical oncologist divide on circulating tumor DNA, whether fewer neoadjuvant cycles could be enough, PD-L1 status, and the EGFR and ALK results that change neoadjuvant strategy. Dr. Lazar shares how he counsels patients before treatment, why none of his patients go to the operating room smoking, how he chooses between lobectomy, segmentectomy, and wedge resection, and why poor communication between teams is the most preventable pitfall on the way to a goal of 28 days from diagnosis to treatment.

